Superluminal Medicines secures $60m to advance rare obesity therapy
Superluminal Medicines will use the proceeds to advance its MC4R agonist candidate into Phase I trials by 2026.
Drug Development
Médunik and Biocodex sign exclusive agreement for Diacomit in Canada
Biocytogen and Qilu Pharmaceutical sign agreement for VHH antibody molecule
Novartis signs $3.2bn drug delivery deal with Alteogen
Ono Pharmaceutical joins forces with Aitia for drug discovery in neurology
Takeda and Weave Bio collaborate on AI-driven automation in drug development
PharmaEssentia’s Besremi receives FDA approval for ET
Kazia closes oversubscribed offering to fund paxalisib’s clinical development
